Segall Bryant & Hamill’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Segall Bryant & Hamill’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-37,455	Closed	-$2.73M	–	502
2023 Q3	$2.73M	Buy	37,455 +100	+0.3%	+$7.99K	0.03%	386
2023 Q2	$3.11M	Sell	37,355 -226	-0.6%	-$18.9K	0.03%	393
2023 Q1	$2.86M	Buy	37,581 +800	+2%	+$66.4K	0.03%	399
2022 Q4	$3.05M	Sell	36,781 -243	-0.7%	-$19.7K	0.03%	384
2022 Q3	$2.95M	Hold	37,024	–	–	0.04%	387
2022 Q2	$2.75M	Sell	37,024 -226	-0.6%	-$17K	0.03%	397
2022 Q1	$3.35M	Buy	+37,250	New	+$3.44M	0.03%	390
2021 Q4	–	Sell	-19,550	Closed	-$2.46M	–	774
2021 Q3	$2.46M	Sell	19,550 -115	-0.6%	-$14.8K	0.02%	442
2021 Q2	$2.67M	Buy	19,665 +17,727	+915%	+$2.33M	0.03%	435
2021 Q1	$263K	Hold	1,938	–	–	﹤0.01%	748
2020 Q4	$272K	Hold	1,938	–	–	﹤0.01%	664
2020 Q3	$216K	Sell	1,938 -75	-4%	-$8.41K	﹤0.01%	668
2020 Q2	$225K	Buy	+2,013	New	+$198K	﹤0.01%	733
2016 Q2	–	Sell	-51,223	Closed	-$2.65M	–	564
2016 Q1	$2.65M	Hold	51,223	–	–	0.07%	267
2015 Q4	$3.6M	Hold	51,223	–	–	0.09%	249
2015 Q3	$3.19M	Buy	+51,223	New	+$4.04M	0.08%	260

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

CHP

Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return

MCM

Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Segall Bryant & Hamill's XBI Position: Q4 2023 in Review

Segall Bryant & Hamill sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 37,455 shares — an estimated $2.73M sold.

Segall Bryant & Hamill first reported a position in XBI in Q3 2015 and held it in 16 quarters. The position peaked at $3.6M in Q4 2015. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

Segall Bryant & Hamill reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
Segall Bryant & Hamill sold 37,455 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $2.73M.
Segall Bryant & Hamill first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and held it in 16 quarters.
Segall Bryant & Hamill's State Street SPDR S&P Biotech ETF position peaked at $3.6M in Q4 2015.
745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Segall Bryant & Hamill's 13F filing for Q4 2023, filed 14 Feb 2024.